The Department of Defense (DoD) has established guidelines for the formulary placement of newly approved innovator drugs under the TRICARE Pharmacy Benefits Program. The process, clarified in the Final Rule published on July 27, 2015, grants the Pharmacy and Therapeutics (P&T) Committee a 120-day evaluation period to assess FDA-approved innovator drugs based on clinical and cost effectiveness. Innovator drugs approved on or after August 26, 2015, will be initially assigned a pending status, and those approved shortly before a P&T meeting will be reviewed in the subsequent meeting. Drugs can be designated across various tiers, influencing copayment structures; Tier 3 drugs may be inaccessible at Military Treatment Facilities unless prescribed for medical necessity. The document also outlines manufacturers' participation in price concessions through solicitation windows before P&T meetings. Notably, the DoD will not entertain clinical presentations for innovator drugs due to the volume involved, emphasizing a streamlined evaluation process. This initiative aims to ensure cost-effective access to necessary medications for military personnel while maintaining compliance with federal guidelines and regulations regarding drug formulary management.

The Price Appendix FAQ provides guidelines for vendors participating in the pricing submission process for formulary categories related to drugs and medical supplies. Vendors must read the Formulary Notes to understand the P&T committee’s decision-making. The document outlines the protocol for filling in specific tables for drug pricing, including columns for National Drug Codes (NDCs), Package Size, and various discount calculations. It covers three pricing sections: BPA, ADP (non-FAMP Discount), and ADP (WAC Discount). Each section instructs vendors to fill in yellow cells while other cells remain locked. The guidelines explain how to manage submissions for multiple NDCs, including the procedure for requesting additional tables if necessary. The emphasis is on compliance and clarity in submitting quotes, with contact information for Point of Contacts (POCs) for questions. This document aids in standardizing submissions to ensure efficient review by the P&T committee in the context of federal grants and RFPs, emphasizing accuracy and adherence to established processes.

The Department of Defense (DoD) will hold a Pharmacy and Therapeutics (P&T) Committee Meeting on August 6-7, 2025, to evaluate newly approved analgesic drugs for the DoD Uniform Formulary. Vendors must submit quotes by May 15, 2025, for several drugs listed under the analgesics category, each categorized as either formulary or non-formulary. The document includes details on pricing per NDC number, indicating that certain drugs will be assessed for cost-sharing and reimbursement approaches aimed at fostering higher-value medications while minimizing lower-value options. Following the meeting, some newly approved agents may be offered preferential status in reimbursement or could face exclusion from the TRICARE pharmacy benefit. Additionally, there is mention of an Additional Discount Program for these agents, specifically designed for TRICARE eligibility. Manufacturers are reminded to include necessary documentation when submitting quotes, highlighting the importance of compliance with established guidelines to ensure proper evaluation. This document serves as a crucial directive for drug manufacturers and stakeholders within federal and military pharmacy operations, aiming to optimize drug formularies and maximize healthcare effectiveness for military personnel.

The document outlines the Department of Defense (DoD) Uniform Formulary process for Antihemophilic Agents, specifically focusing on Non-Factor Agents, with upcoming Purchasing & Therapeutics (P&T) Committee meetings scheduled for August 6-7, 2025. The request for quotes (RFQ) from manufacturers is set to be due by May 15, 2025, for multiple newly approved drugs categorized under this formulary. Each section details various drugs, their National Drug Codes (NDC), dosage forms, package sizes, and stipulates that no quotes have been submitted thus far. Notable points include the potential for agents to be reviewed for prior authorization, the possibility of special reimbursement methods, and the encouragement of high-value products over low-value products. Manufacturers are also reminded to submit executed signature pages with quotes and note that price per unit should remain constant across different package sizes. The document emphasizes maintaining strict compliance with federal regulations, thus ensuring a focus on efficient, cost-effective pharmaceutical use within the DoD medical system for the benefit of service members and their families.

The document outlines the upcoming Department of Defense (DOD) Pharmacy and Therapeutics (P&T) Committee Meeting scheduled for August 6-7, 2025, focusing on the evaluation of Benign Prostatic Hyperplasia (BPH) agents, specifically Selective Alpha-1 Antagonists. Quotes from manufacturers are due by May 15, 2025, for newly approved drugs within this category. Both uniform formulary and non-formulary options are mentioned, with specific National Drug Code (NDC) numbers provided. The document emphasizes the requirement for fully executed signature pages alongside quote submissions and notes that agents may undergo prior authorization and special reimbursement assessments. Recommendations from the committee could favor treating certain non-generic drugs as preferred options (Tier 1) under cost-sharing policies. The document also discusses potential exclusions from the TRICARE pharmacy benefit program and outlines considerations for step therapy regarding submitted quotes. Overall, it serves to inform stakeholders about the procurement process for pharmaceutical agents aimed at improving military healthcare.

The document outlines the details for the Department of Defense (DOD) regarding newly approved drugs within the category of nephrology agents, specifically addressing the DoD Uniform Formulary Class. The upcoming Pharmacy and Therapeutics (P&T) Committee Meeting is scheduled for August 6-7, 2025, with quotes for the pharmaceuticals due by May 15, 2025. It highlights the need for drug manufacturers to submit their quotes alongside fully executed signature pages. Each drug exhibits a specific National Drug Code (NDC) and is categorized as either uniform or non-formulary, with indications of no quotes submitted for multiple scenarios. Additional components include a discussion of an Additional Discount Program (ADP) for agents classified under different Tiers (2 and 3), emphasizing negotiated refunds for pricing discrepancies in retail drug costs. The potential for prior authorization and the recommendation of preferential status for certain drugs are noted as strategies to encourage the use of valuable therapeutic options over less effective alternatives. This initiative demonstrates the DOD's commitment to managing pharmaceutical costs and optimizing the formularies to serve military healthcare needs effectively.

The Department of Defense (DOD) is issuing a Request for Quotation (RFQ) for pharmaceutical agents to be included in the Uniform Formulary (UF) under the Defense Health Agency (DHA). The RFQ provides a structured process for pharmaceutical manufacturers to submit pricing for both Blanket Purchase Agreements (BPA) and Additional Discount Programs (ADP), ensuring cost-effectiveness and clinical effectiveness evaluations. Manufacturers can submit offers before the Pharmacy and Therapeutics (P&T) Committee reviews specific drug classes, with detailed instructions for quote submissions outlined in the document. Key elements include requirements for original signed quotes, the need for a National Drug Code (NDC) Price List, and distinct criteria for pricing depending on whether the product will be supplied to Military Treatment Facilities (MTF) or through retail networks. The document explains the evaluation processes, determining placement on the Basic Core Formulary (BCF) or Extended Core Formulary (ECF), and emphasizes importance of adherence to Federal pricing standards. The RFQ underlines the DOD’s goal to create an integrated pharmacy benefits program while attracting competitive pricing from manufacturers. It facilitates a systematic approach to pricing negotiations and formulary inclusion, critically impacting the availability and accessibility of medications for TRICARE beneficiaries.